Patients HCP
This site is for US residents only.

Understanding BRAF  V600E

in Metastatic Non-Small Cell Lung Cancer

About BRAF V600E

NSCLC is a common type of lung cancer. When it is metastatic (mNSCLC), the cancer cells have spread beyond the lungs to other parts of the body. It can travel through the bloodstream to distant parts of the body, most often to the brain, bones, liver, and adrenal glands.

Gene changes (mutations) have been linked to cancer growth in mNSCLC. In some cases, health care providers may be able to identify specific non-inherited genetic mutations through biomarker testing. With this information, your health care provider may be able to use a therapy specific for your cancer and its mutation(s). Your health care provider can test for BRAF V600E, which is a specific mutation found in mNSCLC and other types of cancer. Approximately 2000 to 3000 people with mNSCLC in the United States may be diagnosed with an abnormal BRAF V600E genetic mutation each year.


What are biomarkers?

To get a treatment that is specific to your type of cancer, your health care provider will want to test for and determine the biomarker of your cancer. Biomarkers represent specific traits within your cancer. If you have a non-inherited genetic mutation, a certain biomarker can alert your health care provider to it.

Mutated gene icon

BRAF V600E is a mutation in the BRAF gene

  • The BRAF gene makes a protein that is involved in sending signals in cells and in cell growth  

  • The BRAF gene may increase the growth and spread of cancer cells

  • This BRAF mutation may be found in some types of cancer, including lung

  • Approximately 2000 to 3000 people with mNSCLC in the United States may be diagnosed with an abnormal BRAF V600E genetic mutation each year

Approximately 2000 to 3000 people with mNSCLC in the United States may be diagnosed with an abnormal BRAF V600E genetic mutation each year
Ask about biomarker testing today

The results of your test can help you and your health care provider find a treatment that is specific for your type of cancer. Ask your health care provider about taking a comprehensive biomarker test.